177 related articles for article (PubMed ID: 36153509)
1. Mutational and transcriptional alterations and clinicopathological factors predict the prognosis of stage I hepatocellular carcinoma : Prediction of stage I HCC prognosis.
Li Z; Gao H; Zhang X; Liu Q; Chen G
BMC Gastroenterol; 2022 Sep; 22(1):427. PubMed ID: 36153509
[TBL] [Abstract][Full Text] [Related]
2. Mutational and Transcriptional Characterization Establishes Prognostic Models for Resectable Lung Squamous Cell Carcinoma.
Liu Y; Duan J; Zhang F; Liu F; Luo X; Shi Y; Lei Y
Cancer Manag Res; 2023; 15():147-163. PubMed ID: 36824152
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of LRP1B mutation-associated prognostic model for hepatocellular carcinoma.
Xu J; Shen X; Zhang B; Su R; Cui M; Yan L; Cao Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34386813
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
6. Bioinformatic Analysis to Identify a Multi-mRNA Signature for the Prediction of Metastasis in Hepatocellular Carcinoma.
Liu L; Wang B; Han Q; Zhen C; Li J; Qu X; Wang F; Kong X; Zheng L
DNA Cell Biol; 2020 Nov; 39(11):2028-2039. PubMed ID: 33147069
[TBL] [Abstract][Full Text] [Related]
7. Genetic expression and mutational profile analysis in different pathologic stages of hepatocellular carcinoma patients.
Gao X; Zhao C; Zhang N; Cui X; Ren Y; Su C; Wu S; Yao Z; Yang J
BMC Cancer; 2021 Jul; 21(1):786. PubMed ID: 34238242
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.
Jiang W; Wu T; Shi X; Xu J
Bioengineered; 2021 Dec; 12(1):7941-7949. PubMed ID: 34612781
[TBL] [Abstract][Full Text] [Related]
9. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis of highly mutated genes in hepatitis B virus-related hepatic carcinoma.
Kong F; Kong D; Yang X; Yuan D; Zhang N; Hua X; You H; Zheng K; Tang R
Cancer Med; 2020 Apr; 9(7):2462-2479. PubMed ID: 32017470
[TBL] [Abstract][Full Text] [Related]
11. Prognosis prediction of stage IV colorectal cancer patients by mRNA transcriptional profile.
Wu B; Yang J; Qin Z; Yang H; Shao J; Shang Y
Cancer Med; 2022 Dec; 11(24):4900-4912. PubMed ID: 35587572
[TBL] [Abstract][Full Text] [Related]
12. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
13. Identification of a seven-gene signature predicting clinical outcome of liver cancer based on tumor mutational burden.
Cui Y; Jiang N
Hum Cell; 2022 Jul; 35(4):1192-1206. PubMed ID: 35622212
[TBL] [Abstract][Full Text] [Related]
14. Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining.
Zhou W; Fang D; He Y; Wei J
J Gastrointest Oncol; 2021 Jun; 12(3):1117-1131. PubMed ID: 34295561
[TBL] [Abstract][Full Text] [Related]
15. LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma.
Yu G; Mu H; Fang F; Zhou H; Li H; Wu Q; Xiong Q; Cui Y
Medicine (Baltimore); 2022 Jul; 101(26):e29763. PubMed ID: 35777027
[TBL] [Abstract][Full Text] [Related]
16.
Wang L; Yan K; He X; Zhu H; Song J; Chen S; Cai S; Zhao Y; Wang L
J Cancer; 2021; 12(1):217-223. PubMed ID: 33391418
[No Abstract] [Full Text] [Related]
17. Identification of a glycolysis-related gene signature for predicting prognosis in patients with hepatocellular carcinoma.
Kong J; Yu G; Si W; Li G; Chai J; Liu Y; Liu J
BMC Cancer; 2022 Feb; 22(1):142. PubMed ID: 35123420
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of PICT1 in patients of hepatocellular carcinoma with wild-type TP53.
Ishibashi M; Kogo R; Shibata K; Ueo H; Uchi R; Matsumura T; Takano Y; Sawada G; Takahashi Y; Mima K; Kurashige J; Akiyoshi S; Iwaya T; Eguchi H; Sudo T; Sugimachi K; Suzuki A; Wakabayashi G; Mori M; Mimori K
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S537-44. PubMed ID: 23532381
[TBL] [Abstract][Full Text] [Related]
19. Construction of a lipid metabolism-related risk model for hepatocellular carcinoma by single cell and machine learning analysis.
Mou L; Pu Z; Luo Y; Quan R; So Y; Jiang H
Front Immunol; 2023; 14():1036562. PubMed ID: 36936948
[TBL] [Abstract][Full Text] [Related]
20. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
Ye S; Zhao XY; Hu XG; Li T; Xu QR; Yang HM; Huang DS; Yang L
Oncol Rep; 2017 Apr; 37(4):2215-2226. PubMed ID: 28350084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
